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Abstract
Background: Disturbances in the regulation of reward and aversion in the brain may underlie disorders such as obesity and 
eating disorders. We previously showed that the cannabis receptor subtype (CB1) inverse agonist rimonabant, an antiobesity 
drug withdrawn due to depressogenic side effects, diminished neural reward responses yet increased aversive responses 
(Horder et al., 2010). Unlike rimonabant, tetrahydrocannabivarin is a neutral CB1 receptor antagonist (Pertwee, 2005) and may 
therefore produce different modulations of the neural reward system. We hypothesized that tetrahydrocannabivarin would, 
unlike rimonabant, leave intact neural reward responses but augment aversive responses.
Methods: We used a within-subject, double-blind design. Twenty healthy volunteers received a single dose of 
tetrahydrocannabivarin (10 mg) and placebo in randomized order on 2 separate occasions. We measured the neural response 
to rewarding (sight and/or flavor of chocolate) and aversive stimuli (picture of moldy strawberries and/or a less pleasant 
strawberry taste) using functional magnetic resonance imaging. Volunteers rated pleasantness, intensity, and wanting for 
each stimulus.
Results: There were no significant differences between groups in subjective ratings. However, tetrahydrocannabivarin increased 
responses to chocolate stimuli in the midbrain, anterior cingulate cortex, caudate, and putamen. Tetrahydrocannabivarin also 
increased responses to aversive stimuli in the amygdala, insula, mid orbitofrontal cortex, caudate, and putamen.
Conclusions: Our findings are the first to show that treatment with the CB1 neutral antagonist tetrahydrocannabivarin 
increases neural responding to rewarding and aversive stimuli. This effect profile suggests therapeutic activity in obesity, 
perhaps with a lowered risk of depressive side effects.
Keywords: reward, THCv, obesity, fMRI, cannabinoid
Introduction
Obesity is among the most frequent preventable causes of mor-
tality in the developed world and is associated with several 
different causes of death, including heart disease, type 2 dia-
betes, and some forms of cancer (see Haslam and James, 2005, 
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for an overview). As part of an effective treatment strategy for 
obesity, it may be useful to supplement behavioral control of 
food intake with the administration of drugs to modulate the 
processes by which the brain generates eating behavior.
The endocannabinoid system in the brain, involving cannab-
inoid type 1 (CB1) receptors, may regulate feeding behavior by 
modulating the reward signal associated with the consumption 
of food (Solinas et al., 2008). Rimonabant, a CB1 antagonist and 
inverse agonist (Pertwee, 2005), has been found to downregulate 
feeding and promote weight loss (Scheen et  al., 2006), acting 
selectively on the consumption of sweet foods (Maccioni et al., 
2008; Mathes et al., 2008). Furthermore, a reduced sensitivity to 
reward and to the effects of cannabinoid compounds has been 
demonstrated in animals with a lower expression of CB1 recep-
tors in the striatum (Friemel et al., 2014).
Rimonabant was, however, withdrawn from clinical use in 
the EU in 2008 following mounting evidence of increased rates 
of depression following its use (Christensen et  al., 2007). The 
rodent studies used in early screening of the drug largely failed 
to detect this potential for depressogenic side effects and in fact 
suggested antidepressant effects instead (Griebel et  al., 2005). 
This highlights the importance of developing a human experi-
mental medicine model for the development of weight-loss 
treatments, such that most adverse psychiatric effects of the 
drug can be detected before clinical use is approved.
Using a human experimental model of reward and aversion 
processing in the brain with functional magnetic resonance 
imaging (fMRI), we previously showed that 7 days’ treatment with 
rimonabant reduced the neural response to rewarding chocolate 
stimuli in key reward areas such as the ventral striatum, puta-
men, and orbitofrontal cortex (OFC) (Horder et al., 2010). We have 
also demonstrated a similar pattern of reduced response using 
the same task with recovered depressed patients (McCabe et al., 
2009). This similarity suggests a mechanism inducing anhedonia, 
which could lead to the increased risk of depressive symptoma-
tology seen in clinical use of the drug. Rimonabant also increased 
lateral OFC activations to the sight and taste of an aversive food, 
and these effects might underlie its ability to promote weight loss.
Like rimonabant, tetrahydrocannabivarin (THCv) acts on 
endocannabinoid CB1 receptors but does so as a neutral antago-
nist (Pertwee, 2005). Neutral antagonists have been suggested as 
a potentially safer alternative to rimonabant in the treatment of 
obesity (Meye et al., 2013) and appear to entail fewer side effects 
such as nausea, while still attenuating operant behavior in animals 
(Bergman et al., 2008). The increased safety and tolerability of neu-
tral antagonists compared with rimonabant is not associated with 
an attenuation of the therapeutically valuable antagonistic action 
at CB1 receptors (Kangas et al., 2013). Most promisingly, recent ani-
mal studies have shown that neutral antagonists appear to reduce 
food intake and weight gain as rimonabant does, but unlike rimon-
abant do not suppress activity in emotion regulation areas such as 
the ventral tegmental area and basolateral amygdala (Meye et al., 
2013). However, how THCv interacts with the reward and aversion 
systems in the human brain is as yet unknown.
Therefore, in this study we aim to examine the effects of 
THCv using our model of reward and aversion processing in 
the human brain. We hypothesize that as THCv is thought to be 
free from the depressogenic side effects seen with rimonabant, 
it will leave intact responses to rewarding stimuli in areas that 
our task (Rolls and McCabe, 2007; McCabe et al., 2009) and other 
studies (O’Doherty et  al., 2001) have shown to be involved in 
reward processing, such as the anterior cingulate cortex (ACC), 
OFC, and striatum. To the extent that THCv nonetheless pro-
duces therapeutically valuable modulations of food aversion, we 
hypothesize increased activations to aversive stimuli in areas 
that have been shown to be involved in the processing of food 
aversion, such as the amygdala, insula, and lateral OFC (Zald 
et al., 2002; McCabe et al., 2010, 2011, 2012).
Materials and Methods
Participants
Twenty participants (10 female), aged 20 to 36 years, completed a 
within-participants, double-blind, placebo-controlled, cross-over 
design. Participants were recruited from the university volun-
teer register and via internet advertisements. Participants were 
assessed with the Structured Clinical Interview for DSM-IV Axis 
I Disorders Schedule (First et al., 1997) to exclude a current or pre-
vious history of major depression or any other Axis 1 disorder. 
Participants also had no history of drug or alcohol misuse and 
did not smoke more than 5 cigarettes per day. Participants were 
right handed according to the Edinburgh Handedness Inventory 
(Oldfield, 1971), had normal or corrected to normal vision, and 
were not taking medications apart from the contraceptive pill. 
Participants had no neurological disorders or contraindications 
for MRI. Ethical approval was obtained from the Oxford Research 
Ethics Committee. After receiving a complete description of the 
study, participants gave written informed consent.
Baseline ratings of mood and anhedonia were collected using 
the Beck Depression Inventory (Beck et al., 1961), the Fawcett-
Clarke Pleasure Scale (Fawcett et al., 1983), the Snaith-Hamilton 
Pleasure Scale (Snaith et al., 1995), and the Temporal Experience 
of Pleasure Scale (Gard et al., 2007). Participants reported liking 
and craving chocolate as measured by our previously designed 
questionnaire (Rolls and McCabe, 2007). Body mass index and 
an Eating Attitudes questionnaire were used to rule out eating 
disorders (Garner et al., 1982) (Table 1).
Experimental Design
Participants completed the task during fMRI, once with the drug 
(10 mg THCv approximately 1 hour before scan to allow for peak 
blood plasma levels to occur) and then again 1 week later with 
the placebo, or vice versa. Both participant and experimenter 
were blind to the treatment condition. We compared brain 
responses with rewarding and aversive food tastes and images. 
Each of the following conditions was applied 9 times in rand-
omized order (supplementary Table S1): chocolate taste, choco-
late picture, chocolate taste and picture, medicinal strawberry 
Table 1. Descriptive Statistics of Demographic Variables
Mean SD
Age (y) 25.4 4.5
BMI 22.1 1.80
SHAPS 17.8 4.7
FCPS 146 21.1
BDI 1.36 2.29
EAT 6.16 5.4
TEPS (state) 84.9 12.2
TEPS (trait) 83.7 10.4
Chocolate craving 6.6 2.0
Chocolate liking 8.7 1.4
Chocolate, frequency of consumption 2.0 1.3
Abbreviations: BDI, Beck Depression Inventory; BMI, body mass index; EAT, 
Eating Attitudes questionnaire; FCPS, Fawcett Clarke Pleasure Scale; SHAPS, 
Snaith-Hamilton Pleasure Scale; TEPS Temporal Experience of Pleasure Scale.
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taste, picture of moldy strawberries, strawberry taste and pic-
ture. Participants were instructed not to eat chocolate for 24 
hours before the scan and to eat only a small breakfast on the 
day of scanning. Mood state and side effects were recorded on 
the study day with the Befindlichkeits scale of mood and energy 
(von Zerssen et al., 1974) and the visual analogue scale (VAS) for 
alertness, disgust, drowsiness, anxiety, happiness, nausea, sad-
ness, withdrawal, and faintness (supplementary Table S4).
Rewarding and Aversive Stimuli
Stimuli were delivered to the participant’s mouth through 3 
Teflon tubes held between the lips. Each tube was connected 
to a separate reservoir via a syringe and a 1-way syringe-acti-
vated check valve (World Precision Instruments, Sarasota, FL), 
which allowed 0.5 mL of any liquid to be delivered manually at 
the time indicated by the computer. The chocolate was liquid 
at room temperature. The aversive stimulus was a medicinal-
flavored strawberry solution (Rosemont Pharmaceuticals, Leeds, 
UK) rated equal in intensity to the chocolate but less pleasant 
in valence (McCabe et  al., 2009). A  control tasteless solution 
(25 × 10−3 mol/L KCl and 2.5×  10−3 mol/L NaHCO3 in distilled H2O) 
was used after every trial that had a taste component, and a 
control gray image of approximately equal intensity to the food 
images was used after every trial that had a sight component. 
This allowed the subtraction on every trial of the appropriate 
control condition. This allows analysis of taste, texture, and 
olfactory effects independently of any somatosensory effects 
produced by introducing a fluid into the mouth. Both the choco-
late and strawberry had approximately the same texture.
Experimental Procedure
At the beginning of each trial, 1 of the 6 conditions chosen by ran-
dom permutation was presented. If the trial involved an oral stimu-
lus, this was delivered in a 0.5-mL aliquot to the participant’s mouth 
at the same time the image was presented. The image was turned 
off after 7 seconds. A small green cross then appeared, prompting 
the participant to swallow what was in the mouth. After a delay 
of 2 seconds, the participant was asked to rate each of the stimuli 
for pleasantness on that trial (+2 being very pleasant and −2 very 
unpleasant), intensity on that trial (0 to +4), and wanting (+2 for 
wanting very much, 0 for neutral, and −2 for very much not want-
ing). The ratings were made with a VAS in which the participant 
moved a bar to the appropriate point on the scale using a button 
box. After the last rating, the gray image indicated delivery of the 
control solution, which also served as a rinse. This was adminis-
tered in the same way as the experimental tastes and the partici-
pant was cued to swallow after 7 seconds. After trials with an image 
but no taste, there was no rinse, but the gray visual stimulus was 
shown to allow an appropriate control as described above.
fMRI Data Acquisition
The experimental protocol was an event-related interleaved 
design with the 6 stimuli described above and in supple-
mentary Table S1. Brain images were acquired with a 3.0-T 
VARIAN/SIEMENS whole-body scanner at the Oxford Centre 
for Functional Magnetic Resonance Imaging. T2*-weighted EPI 
slices were acquired every 2 seconds (TR = 2). Imaging param-
eters were selected to minimize susceptibility and distortion 
artefacts in the OFC (Wilson et  al., 2002). Coronal slices with 
in-plane resolution of 3 × 3 mm and between-plane spacing of 
3 mm were obtained. The matrix size was 64 × 64 and the field of 
view was 192 × 192 mm. Acquisition was carried out during task 
performance yielding 972 volumes in total. A  whole brain T2* 
weighted EPI volume of the above dimensions and an anatomi-
cal T1 volume with coronal plane slice thickness 3 mm and in-
plane resolution of 1.0 × 1.0 mm were also acquired.
fMRI Data Analysis
Imaging data were preprocessed and analyzed using statis-
tical parametric mapping software SPM8. Data preprocess-
ing included realignment, normalization to the Montreal 
Neurological Institute coordinate system, reslicing with sinc 
interpolation, and spatial smoothing with a full-width isotropic 
Gaussian kernel and global scaling. For each voxel, time-series 
nonsphericity was corrected for (Friston et al., 2002) and a low-
pass filter was applied (with a hemodynamic response kernel), 
as was a high-pass filter, with a cutoff period of 128 seconds. 
In the single event design, where each trial contains a single 
event, a general linear model was then applied to the time 
course of activation where stimulus onsets were modeled as 
single impulse response functions and then convolved with 
the canonical hemodynamic response function (Friston et  al., 
1994). Time derivatives were included in the basis function set. 
Following smoothness estimation, linear contrasts of parameter 
estimates were defined to test the specific effects of each condi-
tion with each individual dataset. Voxel values for each contrast 
resulted in a statistical parametric map of the corresponding 
t statistic, which was then transformed into the unit normal 
distribution (SPM z). Movement parameters for each person 
were added as additional regressors in the first-level analyses. 
Second-level fMRI analyses first examined simple main effects 
of task with 1-sample t tests in the placebo test session only 
(supplementary Tables S3-4). To examine the effect of THCv, 
we used the 1-way ANOVA within-participants design imple-
mented in SPM8 for each condition separately and reported all 
data thresholded at P < .05. Regions of interest (ROIs) in which 
we had a priori hypotheses, based on our previous studies using 
this task, were: OFC [26 32  −10] (McCabe et  al., 2010), ACC [−2 
26  20] [10 16  30] (McCabe et  al., 2011, 2012), ventral striatum 
[−12 6 4] (Rolls and McCabe, 2007), insula [−34 16 0] [−32 18 6] 
[42 20 −10], and amygdala [20 −2 −22] (McCabe et al., 2009, 2011, 
2012; Horder et  al., 2010). Peaks within 15 mm of these loca-
tions and within the functional ROIs identified by our 1-sample 
main effects t tests (supplementary Tables S2-3) and which met 
a cluster threshold of 30 contiguous voxels (k = 30) were small 
volume corrected (svc) for multiple comparisons (family wise 
error [FWE], P < .05). Exploratory whole brain analysis was also 
carried out, and clusters were corrected (P < .05 FWE) for multiple 
comparisons. Gender and order were also added as covariates 
of no interest in the SPM8 model. For the plots of peak, contrast 
estimates were extracted using the plots tool in SPM8, and WFU 
Pick Atlas was used to display neural activation (Maldjian et al., 
2003). Activation coordinates are listed in the stereotactic space 
of the Montreal Neurological Institute ICBM 152 brain (Table 2).
Results
Demographic Data
Demographic data analysis (Table 1) revealed participants had 
low depression scores as well as normal scores on the Eating 
Attitudes questionnaire and were in the healthy weight range. 
Participants demonstrated a high level of chocolate craving and 
liking as demonstrated by their responses on the chocolate 
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eating questionnaire. One-way ANOVAs revealed no significant 
effects (P < .05) of gender on any of the demographic measures.
Mood, Energy, and Affect Scores
Repeated-measures ANOVAs were employed to examine the 
effect of drug (placebo/THCv) and time (prescan/postscan) 
on scores of mood, energy, and affect, as measured by the 
Befindlichkeits scale of mood and energy and VAS (supplemen-
tary Table S4). Results revealed there was no main effect of drug 
on mood, energy, or affect (P < .05). To assess any potential con-
founding effects of gender or order (THCv first/placebo first) on 
mood, these factors were included in the analyses as independ-
ent variables. No main effects of gender or order and no gen-
der × drug or order × drug interactions were revealed.
Subjective Ratings of Stimuli
Repeated-measures ANOVAs were used to examine the effect 
of drug (placebo/THCv) on subjective ratings of pleasantness, 
wanting, and intensity of the food stimuli (chocolate taste, 
chocolate picture, chocolate taste and picture, strawberry taste, 
strawberry picture, strawberry taste and picture). There was a 
main effect of condition; as expected, the pleasant chocolate 
stimuli and the less pleasant strawberry stimuli were rated dif-
ferently, but there were no main effects of drug or drug × con-
dition interactions (supplementary Figure S1; supplementary 
Table S5).
Main Effects of Stimuli on BOLD Responses
Tables S2 and S3 provide a summary of the main effects for the 
rewarding chocolate stimuli vs control stimuli and the aver-
sive strawberry stimuli vs control stimuli in the placebo group 
only. As expected, the pleasant chocolate taste and picture 
stimuli activated reward-relevant circuitry, including the ven-
tral striatum, OFC, ACC, and insula (supplementary Table S2). As 
expected, the less pleasant strawberry taste and picture stimuli 
activated circuitry including the amygdala, insula, and lateral 
OFC (supplementary Table S3).
Effect of THCv on BOLD Responses to Food Stimuli
Table  2 provides a summary of the results of the effects of 
THCv. ROI analyses revealed that THCv, compared with pla-
cebo, enhanced BOLD activations in response to the choco-
late sight in the putamen (Figure  1) and ACC (Figure  2),and 
increased BOLD activations in response to the aversive 
strawberry taste and sight in the putamen and amygdala 
(Figure 3). Whole brain analysis revealed that, compared with 
placebo, THCv enhanced BOLD activations in response to the 
chocolate stimuli in the caudate, mid brain, and cingulate 
gyrus (Table  2). There was no effect of THCv on chocolate 
taste alone.
For the less pleasant conditions, we found that THCv 
enhanced activation to the strawberry sight in the insula 
(Figure 4), mid OFC, superior temporal gyrus, and putamen in 
the whole brain analysis. Similar regions such as the insula, mid 
OFC, superior temporal gyrus, thalamus, and caudate were also 
enhanced under the combination condition of strawberry taste 
and sight. The figures display the significant between-group 
differences.
A region of the occipital cortex activated by photic stimu-
lation across all subjects was identified as a ROI. Repeated-
measures ANOVA for drug/placebo in this region confirmed 
no suprathreshold clusters, FWE cluster corrected. Indicating 
that the observed effects of THCv did not result from global 
hemodynamic changes.
Table 2. Blood Oxygen Level Dependent Responses to Rewarding (Chocolate) Stimuli and Aversive Strawberry THCv vs Placebo
Anatomical region
Coordinates (MNI)
Z-score PX Y Z
Chocolate sight
 Putamen 16 10 −6 2.74 .03 svc
 ACC −2 20 36 3.19 .03 svc
 Caudate −8 8 18 4.09 <.001
 Mid brain 6 −6 −2 3.95 <.001
 Cingulate gyrus −18 −28 36 3.8 <.001
Chocolate sight and taste
 Mid cingulate gyrus −14 −8 42 3.5 <.001
Strawberry sight
 Insula 38 10 10 3.46 <.001
 Mid OFC −16 36 −10 3.42 <.001
 STG 54 10 −10 3.43 <.001
 Putamen −26 8 −12 3.3 <.001
Strawberry sight and taste
 Putamen 16 6 −2 2.74 .03 svc
 Amygdala 24 6 −18 2.66 .03 svc
 Insula −38 14 −14 2.98 .005
 Mid OFC −18 32 −10 3.28 .005
 STG 54 10 −10 3.81 .005
 Thalamus 4 −6 6 3.23 .005
 Caudate −8 14 2 3.09 .005
Abbreviations: ACC, anterior cingulate cortex; FWE, family wise error; MNI, Montreal Neurological Institute; OFC, orbitofrontal cortex; STG, superior temporal gyrus; 
svc, small volume corrected; tetrahydrocannabivarin, THCv.
Threshold set at P < .05. P-values: svc (P < .05 FWE-corrected for multiple comparisons). P values: whole brain corrected (P < .05 FWE-corrected for multiple compari-
sons). Gender and order were added as covariates of no interest.
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Figure 1. Left: Chocolate sight. Increase putamen activation under tetrahydrocannabivarin (THCv) compared with placebo, small volume corrected (svc) (z = 2.74, P = .03 
svc family wise error [FWE]-corrected for multiple comparisons). Right: Contrast estimates for putamen centered at 16 10 −6 for chocolate sight. Error bars show 1 SEM.
Figure 2. Left: Chocolate sight. Increased anterior cingulate activation under tetrahydrocannabivarin (THCv) compared with placebo, small volume corrected (svc) 
(z = 3.19, P = .03 svc family wise error [FWE]-corrected for multiple comparisons). Right: Contrast estimates for anterior cingulate centered at −2 20 36 for chocolate sight. 
Error bars show 1 SEM.
Figure 3. Left: Strawberry sight and taste. Increased amygdala activation under tetrahydrocannabivarin (THCv) compared with placebo, small volume corrected (svc) 
(z = 2.66, P = .03 svc family wise error [FWE]-corrected for multiple comparisons). Right: Contrast estimates for amygdala centered at 24 6 −18 for strawberry sight and 
taste. Error bars show 1 SEM.
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Discussion
The aim of the current study was to examine the effects of a sin-
gle dose (10 mg) of the CB1 receptor neutral antagonist THCv on 
the neural processing of rewarding and aversive food stimuli in 
the healthy human brain. We found that there were no subjec-
tive effects of a single dose of THCv on ratings of pleasantness, 
wanting, and intensity of the stimuli made inside the scanner; 
however, we did detect significant neural differences. This study 
is thus further evidence that neuroimaging may be a more sen-
sitive measure than a subjective report of the early effects of 
drug treatments and can provide an understanding of the neu-
ral mechanisms through which behavioral changes eventually 
emerge with repeated treatment (Harmer and Cowen, 2013).
In this study, we found enhancement of activation under 
the positive chocolate stimuli conditions in the ACC and stria-
tum and in the striatum (caudate) mid cingulate and midbrain. 
Consistent with these findings, the striatal region has been 
shown to have a dense concentration of cannabinoid receptors 
located on striatal projection neurons (Herkenham et al., 1991a), 
and the cingulate cortex also has high levels of cannabinoid 
receptors (Sim-Selley et al., 2002). Both these regions have been 
previously highlighted in relation to reward processing and the 
endocannabinoid system (van Hell et al., 2012). This outcome is 
in direct contrast to our previous study, which found that the 
CB1 antagonist/inverse agonist rimonabant reduced activations 
to reward in key reward areas such as the OFC, ventral stria-
tum, and putamen. We expected that, unlike rimonabant (with 
its depressogenic side effects), THCv would not reduce activa-
tions to the rewarding chocolate conditions in our study. In fact, 
we found that THCv increased activation to the sight of choco-
late in a very similar region to that which was reduced under 
rimonabant, the ventral striatum/putamen region. These results 
are important in that reduced reward processing has been previ-
ously shown in patients with depression (Keedwell et al., 2005) 
and also in our own studies in recovered depressed patients 
(McCabe et al., 2009). Thus, the current results support the idea 
that THCv does not impair reward function, and this may be 
related to a potentially safer side effect profile.
Interestingly studies in obesity show a hypofunctioning 
striatal response to food taste, which can be further reduced 
by overeating (Stice et  al., 2010). In our study, we examined 
healthy people and found effects on reward response to sight 
but less to taste. Given that obese individuals have a greatly 
reduced response to reward to begin with, THCv may produce 
a more pronounced enhancement of reward response to taste 
than observed in the present study for healthy individuals. 
This enhancement could act to rebalance the reward system 
in response to food and help obese people reduce the overeat-
ing that may occur as an overcompensation for hypofunction-
ing striatal regions. Our results with healthy people are a first 
step towards understanding the action of THCv. The present 
study would need to be repeated in obese individuals to clarify 
whether THCv modulates reward activity to food stimuli in the 
same way and whether over time this leads to a reduction in 
eating.
We also found that THCv increased activations to the aver-
sive conditions in a ventral striatum/putamen region similar 
to that in which aversion-related response was reduced under 
rimonabant. We discussed in our previous paper how this might 
suggest that rimonabant reduced activity in motivational areas 
to both pleasant and less pleasant stimuli (Horder et al., 2010). 
However, in the present study, regions such as the caudate and 
the putamen showed increased activity under THCv for both the 
positive and negative visual stimuli. This might indicate that 
THCv is not dampening down motivational processes, as these 
areas are involved in motivation and action in relation to both 
positive and negative events. Taken together, our results support 
the notion that THCv is less likely to cause depression-like side 
effects in humans, because it does not attenuate activations to 
either positively or negatively valenced stimuli in key motiva-
tion areas of the brain.
We also found enhancement in the mid brain to the choco-
late condition and not the aversive condition under THCv com-
pared with placebo. Studies have revealed that CB1 receptors 
are on axon terminals that impinge upon midbrain neurons 
(Melis et al., 2004; Riegel and Lupica, 2004; Matyas et al., 2008) 
and that this might be a mechanism by which cannabinoids can 
modify reward behavior through actions in the ventral tegmen-
tal area of the midbrain (Wang and Lupica, 2014). Interestingly, 
we only found modulation of this region in relation to the posi-
tive reward condition, which is consistent with the report that 
dopamine neurons preferentially report stimuli with appe-
titive rather than aversive motivational value (Mirenowicz and 
Schultz, 1996). This result again suggests that THCv does not 
inhibit the neural response to reward and may even enhance it. 
However, it is worth mentioning that we did not find any subjec-
tive effects of the drug, which most likely was due to the acute 
single dose. Thus, future studies would benefit from the exami-
nation of longer term treatments and higher doses to truly map 
the mechanism of action and how potential subjective effects 
might be related to the neural responses.
In the current study, we also found that for the combina-
tion of the taste and sight of the less pleasant stimuli there was 
Figure 4. Left: Strawberry sight. Increased insula activation under tetrahydrocannabivarin (THCv) compared with placebo, small volume corrected (svc) (z = 3.46, P = .005 
svc family wise error [FWE]-corrected for multiple comparisons). Right: Contrast estimates for insula centered at 38 10 10 for strawberry sight. Error bars show 1 SEM.
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enhanced activation under THCv in the amygdala and insula. 
Aversive taste processing has been shown to involve the amyg-
dala (Nitschke et al., 2006), and studies have identified distinct 
amygdala neuronal populations responsible for processing 
aversive information (Paton et al., 2006). The anterior insula is 
known to be part of the gustatory system (Faurion et al., 1998) 
but is also involved in the processing of aversive stimuli and dis-
gust (Liu et al., 2011). Although no studies to date have directly 
examined the effect of THCv on the neural basis of aversive food 
processing in humans, it is interesting to note that one common 
feature between rimonabant and THCv is that both treatments 
increased activation to the aversive taste and sight condition in 
areas thought to be involved in negative information processing, 
such as the lateral OFC under rimonabant and the amygdala, 
insula, thalamus, and caudate under THCv. Although the amyg-
dala and insula do indeed respond to positive information, in 
the present study we found that THCv increased amygdala and 
insula activity only to the aversive stimuli and in the case of the 
amygdala only when a taste was presented. This is likely to be a 
specific valence effect acting on the consummatory aspect of the 
unpleasant food and thus might be a mechanism by which THCv 
can make less pleasant food more salient and more unpleasant. 
By increasing the tendency on the part of appetitive regions to 
assess food as unpleasant, this effect may decrease time to sati-
ety as food becomes unpleasant on repeated consumption, in 
turn reducing overall consumption. This is plausible in light of 
a study by Tallett et al. (2008), which found that the behavioral 
satiety sequence (time to stop feeding) was accelerated under 
a rimonabant and naloxone combination in rats. Because one 
aspect of satiety is the gradual change in the subjective experi-
ence of food from pleasant to unpleasant (Saker et al., 2014), it is 
possible that our finding of increased brain activity to less pleas-
ant food stimuli under THCv might be a mechanism by which 
drugs that aid food reduction decrease time to satiety.
Analysis also revealed increased activity to the less pleas-
ant food stimuli under THCv in the mid OFC. The OFC is a key 
player in the reward system and has been shown to be specifi-
cally related to the reward value of a stimulus and therefore to 
the decisions made based upon choices and preferences (Levy 
and Glimcher, 2012). It is also highly populated with cannabi-
noid receptors (Herkenham et  al., 1991b). Our results indicate 
that THCv can modulate activity in OFC during the presenta-
tion of both the less pleasant taste and sight. This could be a 
mechanism by which choices and decisions made in relation to 
food preferences are modulated under cannabinoid antagonist 
treatment.
We also found that there was increased activity to the aver-
sive stimuli under THCv in the superior temporal gyrus, an 
auditory and linguistic region of the human brain. A  recent 
study examining the effects of THC on the human brain found 
that activity in this same region was decreased under THC in 
healthy volunteers and that the decrease was associated with 
an increase in psychotic symptoms (Winton-Brown et al., 2011). 
Right hemisphere activations play a role in resolving ambigu-
ity in language (Harpaz et al., 2009), and as our results are only 
on the right hemisphere, perhaps THCv is having some effects 
on the clarity of decision making in the less pleasant condi-
tions. This is, of course, speculative, as we did not have a task 
in this study that directly addressed the processing of auditory 
or linguistic cues.
In our recent study examining the effects of naltrexone (an 
opioid drug used to treat alcoholism) using the same task as 
described here, we found naltrexone also enhanced responses 
to aversive stimuli but had no effects on the striatum response 
to reward (Murray et  al., 2014). Naltrexone is by itself a weak 
antiobesity agent (Atkinson et  al., 1985), and this may be 
because it has limited effects on the ventral striatal response to 
reward. THCv, on the other hand, enhanced striatal responses 
to the sight of chocolate in the present study. As it has been 
shown that people “at risk” of obesity have an increased neural 
response to reward (Stice et al., 2008) as do binge eaters (Filbey 
et al., 2012; Schienle et al., 2009), we suggested that drugs such 
as naltrexone that reduce reward are effective as preventa-
tive treatments in those “at risk” of obesity or binge eating but 
not for people who are currently overweight and already have 
reduced reward processing.
A recent study by Wang et al. (2014) tested the effects of a 
combined bupropion (dopamine reuptake inhibitor) and nal-
trexone treatment on brain responses to food cues in overweight 
females. Interestingly, they found no effects of the food pictures 
in the striatum, a finding that the authors attributed to the task’s 
lack of sensitivity, but which could also indicate the hypofunc-
tioning reward systems of the overweight volunteers. Similar to 
our results, they found enhancement in the anterior cingulate 
to food cues in drug vs placebo, which they describe as being a 
mechanism by which enhanced inhibitory control over food is 
induced due to the role of the ACC in cognitive control. Taken 
together, our results in healthy people show some enhancement 
in striatal and cognitive control areas that might make THCv a 
beneficial treatment in obese individuals with hypofunctioning 
reward systems and lack of control over food intake.
It should be noted that THCv also has a high affinity as a 
partial agonist for CB2 receptors, and studies have shown that 
CB2 receptors, although thought to be primarily involved in 
immune function (McPartland et al., 2014), can also be antago-
nized by THCv (Pertwee, 2005; Thomas et al., 2005). As CB2 recep-
tor agonists act on the brain to induce food intake (Emadi et al., 
2011), it is possible that CB2 antagonism by THCv could also 
reduce food intake. However, to date, how effects on CB2 recep-
tors are related to neural responses to food in humans is as yet 
unknown, so effects of THCv on CB2 receptors in relation to food 
cannot be ruled out (Mechoulam et al., 2014).
In conclusion, our results are the first to examine the effects 
of THCv on the neural response to reward and aversion in the 
human brain. We found that THCv did not reduce reward pro-
cessing but rather enhanced activations in key reward and aver-
sion processing areas. There are contrasts between these effects 
and those we previously identified of rimonabant, indicating 
that there may be meaningful differences between the clinical 
effects of rimonabant and THCV. These data support functional 
neuroimaging as an important tool in drug development, one 
that allows the neural mechanisms underlying behavior to be 
studied in humans. It thereby may aid the detection of clinically 
relevant effects of treatments over shorter periods of time and 
speed the development of effective drugs and the rejection of 
unsuitable ones.
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